Recent Advances in the Treatment of Alopecia Areata

The Role of Health Care Providers in Raising Awareness About Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

December 2nd 2024

Future Directions in the Treatment of Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

December 2nd 2024

Challenges With the Use of JAK Inhibitors

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 25th 2024

Considerations Regarding Patient Selection for JAK Inhibitors

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 25th 2024

Assessing Risk and Safety of JAK Inhibitors

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 18th 2024

Panelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and headache and acne for deuruxolitinib.

Real-World Clinical Experience With JAK Inhibitors

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 18th 2024

Panelists discuss their clinical experiences with Janus kinase (JAK) inhibitors for treating alopecia, noting observed differences in outcomes and tolerability among various systemic JAK inhibitors, while highlighting the advantages of these therapies over traditional local and systemic treatment options.

Review of FDA Approved JAK Inhibitors for Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 11th 2024

Panelists discuss the long-term study results for baricitinib in alopecia areata, noting that nearly 90% of patients maintained a SALT score of ≤20 from week 52 to week 104, with over 70% achieving a SALT score of ≤10, while also addressing the reported treatment-emergent adverse events (TEAEs), which were mostly mild to moderate, with common events including COVID-19 infection and upper respiratory tract infections.

JAK Inhibition in the Treatment of Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 11th 2024

Panelists discuss the differences in mechanisms of action among the FDA-approved Janus kinase (JAK) inhibitors for alopecia, including baricitinib, deuruxolitinib, and ritlecitinib, and explore how selective inhibition differs from pan-inhibition in influencing treatment efficacy.

Patient Factors and Other Considerations for Treatment Selection

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 4th 2024

Panelists discuss the factors that guide their treatment decisions for alopecia areata, including severity, presentation, patient characteristics, and comorbid conditions, while also addressing how they prioritize these factors and incorporate patients’ expectations into their treatment strategy.

Treatment Options for Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

November 4th 2024

Panelists discuss how they assess the standard of care for managing alopecia areata.

The Pathophysiology of Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

October 28th 2024

Panelists discuss the pathophysiology of alopecia areata, including the risk factors for disease onset and progression, as well as the role of Janus kinase (JAK) in the disease’s mechanisms.

The Benefits of Early Diagnosis of Alopecia Areata

ByArash Mostaghimi, MD, MPH,Amy McMichael, MD,Brittany G. Craiglow, MD

October 28th 2024

Panelists discuss the importance of early diagnosis of alopecia areata and how it influences treatment strategies and potential patient outcomes.

Recent Advances in the Treatment of Alopecia Areata

ByRaj Chovatiya, MD, PhD,George Han, MD, PhD,Brett King, MD, PhD

April 5th 2023

In this MEDcast episode, Raj Chovatiya, MD, PhD, and George Han, MD, PhD, interview Brett King, MD, PhD, to discuss the latest advances in the treatment of alopecia areata.